









Markets
/
Stocks
/
nasdaq-dnli
/

Denali Therapeutics Inc

DNLI

17.440USD

+0.290+1.69%

Close 11/14, 16:00（ET）Quotes delayed by 15 min

2.56BMarket Cap

LossP/E TTM



Denali Therapeutics Inc

17.440

+0.290+1.69%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Denali Therapeutics Inc

Currency: USD Updated: 2025-11-13

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Denali Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

48 / 406

Overall Ranking

138 / 4603

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 19 analysts

Buy

Current Rating

31.533

Target Price

+79.98%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Denali Therapeutics Inc Highlights

StrengthsRisks

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -5.89, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 145.41M shares, decreasing 4.21% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 2.21M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-13

The company's current financial score is 5.27, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.27

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.57

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.97

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Denali Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-13

The company’s current valuation score is 6.48, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -5.89, which is -26.93% below the recent high of -4.30 and -388.27% above the recent low of -28.75.

Score

Industry at a Glance

Previous score

6.48

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 48/406

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-13

The company’s current earnings forecast score is 8.95, which is higher than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Denali Therapeutics Inc is 30.00, with a high of 40.00 and a low of 24.00.

Score

Industry at a Glance

Previous score

8.95

Change

Support & Resistance

No Data

Analyst Rating

Based on 19 analysts

Buy

Current Rating

31.533

Target Price

+83.87%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

523

Total

Median

Average

Company name

Ratings

Analysts

Denali Therapeutics Inc

DNLI

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

105

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-13

The company’s current price momentum score is 8.92, which is higher than the Biotechnology & Medical Research industry's average of 6.59. Sideways: Currently, the stock price is trading between the resistance level at 19.32 and the support level at 14.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.07

Change

-0.15

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.311

Buy

RSI(14)

61.494

Neutral

STOCH(KDJ)(9,3,3)

72.608

Neutral

ATR(14)

1.156

High Vlolatility

CCI(14)

103.396

Buy

Williams %R

25.455

Buy

TRIX(12,20)

0.199

Sell

StochRSI(14)

83.153

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

17.058

Buy

MA10

15.989

Buy

MA20

16.196

Buy

MA50

15.257

Buy

MA100

14.889

Buy

MA200

15.281

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-13

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.13. The latest institutional shareholding proportion is 99.14%, representing a quarter-over-quarter decrease of 5.89%. The largest institutional shareholder is The Vanguard, holding a total of 11.96M shares, representing 8.15% of shares outstanding, with 2.17% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

11.78M

+0.09%

Baillie Gifford & Co.

Star Investors

11.96M

-1.11%

BlackRock Institutional Trust Company, N.A.

9.87M

-1.68%

Fidelity Management & Research Company LLC

7.41M

+1.72%

Biogen Inc

7.16M

-43.89%

T. Rowe Price Associates, Inc.

Star Investors

6.46M

+51.71%

Wellington Management Company, LLP

5.66M

-50.35%

Temasek Holdings Pte. Ltd.

5.36M

Capital Research Global Investors

4.75M

-0.31%

State Street Investment Management (US)

4.52M

+1.28%

Risk Assessment

Currency: USD Updated: 2025-11-13

The company’s current risk assessment score is 5.73, which is higher than the Biotechnology & Medical Research industry's average of 3.46. The company's beta value is 1.12. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.